Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543497 | 0.76 | HSD11B1 (0.47) | HSD11B1EPHX2CHRM2CHRM4CHRM5 | |
| SCHEMBL14344812 | 0.75 | PSEN1 (0.42) | HSD11B1EPHX2 | |
| SCHEMBL5095125 | 0.74 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL8909762 | 0.73 | SLC6A3 (0.35) | HSD11B1 | |
| SCHEMBL17082726 | 0.73 | HSD11B1 (0.56) | HSD11B1 | |
| SCHEMBL4547709 | 0.68 | — | — | |
| SCHEMBL26934662 | 0.65 | F2 (0.42) | HSD11B1DDB1CRBN | |
| SCHEMBL8779970 | 0.65 | F2 (0.42) | HSD11B1DDB1CRBN | |
| SCHEMBL251038 | 0.65 | HSD11B1 (0.36) | HSD11B1EPHX2CHRM2CHRM4CHRM5 | |
| SCHEMBL548733 | 0.64 | CYP2C9 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061793-A2 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | Novacardia, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080070934-A1 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | MUGERDITICHIAN MARK | 2008-03-20 | — | — | US | disclosed |
| US-20080070934-A1 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | MUGERDITICHIAN MARK | 2008-03-20 | — | — | US | disclosed |
| WO-2008024277-A2 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | NOVACARDIA, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070934-A1 | KW-3902 CONJUGATES THAT DO NOT CROSS THE BLOOD-BRAIN BARRIER | DCX, FLT4, KDR | HSD11B1 1771/4885EPHX2 75/4885CHRNB2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.